12Chapter 1REFERENCES1. Ravitch MM: Cost containment insurgery: the nature of the problem. BullAm Coll Surg 1980; 65(4): 10-13.2. Callahan D: Rationing medical progress.The way to affordable health care. NEngl J Med 1990; 322(25): 1810-1813.3. Eddy DM: Clinical decision making:from theory to practice. Health systemreform. Will controlling costs requirerationing services? JAMA 1994; 272(4):324-328.4. Drummond MF, O'Brien B, Stoddart GL,Torrance GW: Methods for the economicevaluation of health care programmes.New York: Oxford University Press;1997.5. Gold MR, Siegel JE, Russell LB,Weinstein MC (eds): Cost-effectivenessin health and medicine. New York:Oxford University Press; 1996.6. Williams A: Cost-effectiveness analysis:is it ethical? J Med Ethics 1992; 18(1):7-11.7. Stolk EA, Post HA, Rutten FFH,Molenaar JC, Busschbach JJV: Costeffectivenessof neonatal surgery: areview. J Pediatr Surg 2000; 35(4):588-592.8. Extracorporeal Life SupportOrganization: ECLS Registry Report.International summary. January, 2004.Ann Arbor, MI: Extracorporeal LifeSupport Organization; 2004.9. Warner KE, Hutton RC: Cost-benefit andcost-effectiveness analysis in healthcare. Growth and composition of theliterature. Med Care 1980; 18(11):1069-1084.10. Elixhauser A, Luce BR, Taylor WR,Reblando J: Health care CBA/CEA: anupdate on the growth and compositionof the literature. Med Care 1993; 31(7Suppl.): JS1-JS11.11. Elixhauser A, Halpern M, Schmier J,Luce BR: Health care CBA and CEA from1991 to 1996: an updated bibliography.Med Care 1998; 36(5 Suppl): MS1-MS9,MS18-MS147.12. Neumann PJ, Greenberg D, OlchanskiNV, Stone PW, Rosen AB: Growth andquality of the cost-utility literature,1976-2001. Value Health 2005; 8(1):3-9.13. Hackam DJ, Superina RA, Pearl RH:Single-stage repair of Hirschsprung'sdisease: a comparison of 109 patientsover 5 years. J Pediatr Surg 1997;32(7): 1028-1032.14. Roberts TE: Economic evaluation andrandomised controlled trial ofextracorporeal membrane oxygenation:UK collaborative trial. Br Med J 1998;317(7163): 911-916.15. Baraldini V, Spitz L, Pierro A: Evidencebasedoperations in paediatric surgery.Pediatr Surg Int 1998; 13(5-6): 331-335.16. Frader JE, Flanagan-Klygis E:Innovation and research in pediatricsurgery. Semin Pediatr Surg 2001;10(4): 198-203.17. Hardin WD, Stylianos S, Lally KP:Evidence-based practice in pediatricsurgery. J Pediatr Surg 1999; 34(5):908-913.18. Rangel SJ, Kelsey J, Henry MCW, MossRL: Critical analysis of clinical researchreporting in pediatric surgery: justifyingthe need for a new standard. J PediatrSurg 2003; 38(12): 1739-1743.19. Chew RT, Sprague S, Thoma A: Asystematic review of utilitymeasurements in the surgical literature.J Am Coll Surg 2005; 200(6): 954-964.
Introduction 1320. Oostenbrink JB, Bouwmans CAM,Koopmanschap MA, Rutten FFH: Manualfor costing research. Methods andguideline prices for economicevaluations in health care. 2004Updated edition [in Dutch]. Diemen:Health Care Insurance Board; 2004.21. Canadian Coordinating Office for HealthTechnology Assessment: A guidancedocument for the costing process.Version 1.0. Ottawa: CanadianCoordinating Office for HealthTechnology Assessment (CCOHTA);1996.22. Canadian Coordinating Office for HealthTechnology Assessment: Guidelines foreconomic evaluation ofpharmaceuticals: Canada. 2nd edition.Ottawa: Canadian Coordinating Officefor Health Technology Assessment(CCOHTA); 1997.23. Commonwealth Department of Healthand Ageing: Guidelines for thepharmaceutical industry on preparationof submissions to the PharmaceuticalBenefits Advisory Committee. Canberra:Commonwealth Department of Healthand Ageing; 2002.24. National Institute for ClinicalExcellence: Guidance for manufacturersand sponsors. Technology appraisalsprocess series no. 5. London: NationalInstitute for Clinical Excellence; 2001.25. Norwegian Medicines Agency:Norwegian guidelines forpharmacoeconomic analysis inconnection with applications forreimbursement. Available at:http://www.legemiddelverket.no/eng/reg/pharmacoeconomic-analysisguidelines.htm.Accessed August 16,2005.26. Rovira J, Antoñanzas F: Economicanalysis of health technologies andprogrammes. A Spanish proposal formethodological standardisation.Pharmacoeconomics 1995; 8(3): 245-252.27. Hout BAv: Whom and how to treat:weighing the costs and effects. Scand JGastroenterol Suppl 2003; (239): 3-10.28. Meltzer D: Accounting for future costsin medical cost-effectiveness analysis. JHealth Econ 1997; 16: 33-64.29. Russell LB: Is prevention better thancure? Washington D.C.: The BrookingsInstitution; 1986.30. Weinstein MC, Siegel JE, Gold MR,Kamlet MS, Russell LB:Recommendations of the Panel on Cost-Effectiveness in Health and Medicine.JAMA 1996; 276(15): 1253-1258.31. Etzioni R, Ramsey SD, Berry K, BrownM: The impact of including futuremedical care costs when estimating thecosts attributable to a disease: acolorectal cancer case study. HealthEcon 2001; 10(3): 245-256.32. Manns B, Meltzer D, Taub K, DonaldsonC: Illustrating the impact of includingfuture costs in economic evaluations:an application to end-stage renaldisease care. Health Econ 2003;12(11): 949-958.33. Stone PW, Chapman RH, Sandberg EA,Liljas B, Neumann PJ: Measuring costsin cost-utility analyses. Variations in theliterature. Int J Technol Assess HealthCare 2000; 16(1): 111-124.34. Brouwer WBF, Koopmanschap MA,Rutten FFH: Patient and informalcaregiver time in cost-effectivenessanalysis. A response to therecommendations of the WashingtonPanel. Int J Technol Assess Health Care1998; 14(3): 505-513.35. Koopmanschap MA, Rutten FFH, IneveldBMv, Roijen Lv: The friction costmethod for measuring indirect costs ofdisease. J Health Econ 1995; 14(2):171-189.36. Johannesson M, Karlsson G: The frictioncost method: a comment. J Health Econ1997; 16(2): 249-255.
- Page 3: COST-EFFECTIVENESS OF NEONATAL SURG
- Page 6 and 7: DOCTORAL COMMITTEEPromotors:Prof.dr
- Page 9 and 10: PUBLICATIONSChapters 2 to 7 are bas
- Page 11: 6ChapterINFORMAL CARE FOR CHILDREN
- Page 14 and 15: 2Chapter 11.1 BACKGROUND AND MOTIVA
- Page 16 and 17: 4Chapter 1provides a good overview
- Page 18 and 19: 6Chapter 1disability, and death of
- Page 21: Introduction 9particular equity pri
- Page 27 and 28: Introduction 1554. Heyman MB, Harma
- Page 29 and 30: THE COST-EFFECTIVENESS OFTREATMENT
- Page 31: Cost-Effectiveness of Treatment for
- Page 35 and 36: Cost-Effectiveness of Treatment for
- Page 37 and 38: Cost-Effectiveness of Treatment for
- Page 39 and 40: Cost-Effectiveness of Treatment for
- Page 41 and 42: Cost-Effectiveness of Treatment for
- Page 43 and 44: Cost-Effectiveness of Treatment for
- Page 45: Cost-Effectiveness of Treatment for
- Page 48 and 49: 36Chapter 3ABSTRACTBackground/Purpo
- Page 50 and 51: 38Chapter 33.2 MATERIALS AND METHOD
- Page 52 and 53: 40Chapter 3child's date of birth) a
- Page 54 and 55: 42Chapter 3diaphragm was closed (Ta
- Page 56 and 57: 44Chapter 3Total costs of treatment
- Page 58 and 59: 46Chapter 3Regarding the treatment
- Page 60 and 61: 48Chapter 3REFERENCES1. Stolk EA, P
- Page 62 and 63: 50Chapter 332. Jaillard S, Pierrat
- Page 64 and 65: 52Chapter 4ABSTRACTAims:To examine
- Page 66 and 67: 54Chapter 4Outcome measuresThe pati
- Page 68 and 69: 56Chapter 4Clearly, the symptoms st
- Page 70 and 71: 58Chapter 4The respondents did not
- Page 72 and 73:
60Chapter 4Table 4.4TAIQOL Scores o
- Page 74 and 75:
62Chapter 44.4 DISCUSSIONIn this pa
- Page 76 and 77:
64Chapter 4ACKNOWLEDGMENTSWe are in
- Page 78 and 79:
66Chapter 418. Coons SJ, Rao S, Kei
- Page 80 and 81:
68Chapter 5ABSTRACTObjective:Extrac
- Page 82 and 83:
70Chapter 5treatment. 26,27 Finally
- Page 84 and 85:
72Chapter 5CostsOnly direct costs w
- Page 86 and 87:
74Chapter 5summarized in Table 5.2.
- Page 88 and 89:
76Chapter 5Table 5.3 Direct Medical
- Page 90 and 91:
78Chapter 5Figure 5.3 illustrates o
- Page 92 and 93:
80Chapter 5severely ill newborns—
- Page 94 and 95:
82Chapter 5REFERENCES1. Bartlett RH
- Page 96 and 97:
84Chapter 533. Meinert CL: Extracor
- Page 98 and 99:
86Chapter 568. Hui TT, Danielson PD
- Page 100 and 101:
88Chapter 6ABSTRACTObjective:To inv
- Page 102 and 103:
90Chapter 6a rule. The health-relat
- Page 104 and 105:
92Chapter 6Regression analysis of h
- Page 106 and 107:
94Chapter 6that caregiving for thei
- Page 108 and 109:
96Chapter 6Table 6.5 CareQol Compar
- Page 110 and 111:
98Chapter 6children with a disabili
- Page 112 and 113:
100Chapter 6This study was of impor
- Page 114 and 115:
102Chapter 618. Poley MJ, Stolk EA,
- Page 116 and 117:
104Chapter 654. Boman KK, Viksten J
- Page 118 and 119:
106Chapter 7ABSTRACTMortality rates
- Page 120 and 121:
108Chapter 77.2 THE RELEVANCE OF CO
- Page 122 and 123:
110Chapter 7In the early 2000s, our
- Page 124 and 125:
112Chapter 7Table 7.1 Economic Eval
- Page 126 and 127:
114Chapter 7More from a policy pers
- Page 128 and 129:
116Chapter 7also expect that life-s
- Page 130 and 131:
118Chapter 7entirely justified, for
- Page 132 and 133:
120Chapter 723. Sydorak RM, Nijagal
- Page 134 and 135:
122Chapter 765. Glaser AW, Davies K
- Page 137 and 138:
GENERAL DISCUSSION:A GUIDED TOURPRO
- Page 139 and 140:
General Discussion: A Guided Tour P
- Page 141 and 142:
General Discussion: A Guided Tour P
- Page 143 and 144:
General Discussion: A Guided Tour P
- Page 145 and 146:
General Discussion: A Guided Tour P
- Page 147 and 148:
General Discussion: A Guided Tour P
- Page 149 and 150:
General Discussion: A Guided Tour P
- Page 151:
General Discussion: A Guided Tour P
- Page 154 and 155:
142GlossaryCharge (or: tariff)A pri
- Page 156 and 157:
144Glossaryefficient one. We are th
- Page 159 and 160:
SUMMARY
- Page 161 and 162:
Summary 149mortality. Finally, it i
- Page 163 and 164:
Summary 151neonatal surgery. It is
- Page 165 and 166:
SAMENVATTING
- Page 167 and 168:
Samenvatting 155zoals directe niet-
- Page 169 and 170:
Samenvatting 157Hoofdstuk 6 gaat ve
- Page 171:
Samenvatting 159vereisen, waarvoor
- Page 174 and 175:
162AcknowledgmentsAlthough I am ind
- Page 176:
About the AuthorBorn in De Meern (N